tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Daniel Brims, 10 are a BUY (90.91%), 1 are a HOLD (9.09%).
Analyst Daniel Brims, currently employed at CANTOR FITZGERALD, carries an average stock price target met ratio of 80% that have a potential upside of 37.29% achieved within 600 days.
Daniel Brims’s has documented 23 price targets and ratings displayed on 5 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on TTPH, Tetraphase Pharmaceuticals at 09-Sep-2015.
Analyst best performing recommendations are on TTPH (TETRAPHASE PHARMACEUTICALS).
The best stock recommendation documented was for TTPH (TETRAPHASE PHARMACEUTICALS) at 9/9/2015. The price target of $220 was fulfilled within 9 days with a profit of $30.2 (15.91%) receiving and performance score of 17.68.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold
6 years 2 months 1 days ago
(07-May-2020)
1/2 (50%)
$36.05 (72.09%)
304
Hold Since 03-Sep-2019
$140
6 years 10 months 5 days ago
(03-Sep-2019)
0/3 (0%)
$69.6 (98.86%)
Buy Since 19-Nov-2015
$4
$1.8 (81.82%)
7 years 1 months 29 days ago
(09-May-2019)
1/2 (50%)
$-16 (-80.00%)
151
Buy Since 11-Sep-2017
$4
$1.8 (81.82%)
7 years 3 months 23 days ago
(15-Mar-2019)
1/3 (33.33%)
$-24.2 (-85.82%)
206
Buy Since 12-Feb-2018
$120
$117.8 (5354.55%)
$220
8 years 4 months 10 days ago
(28-Feb-2018)
0/2 (0%)
$63.8 (113.52%)
What Year was the first public recommendation made by Daniel Brims?
